Masilamani Elizabeth Sobhia

Prof. Masilamani Elizabeth Sobhia

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Diseases
Verified
Journal Article
Open access
PDF file
KRKakarla Ramakrishna
Kakarla Ramakrishna
PKPraditha Karuturi
Praditha Karuturi
QSQueen Siakabinga
Queen Siakabinga
GAGajendra T A
Gajendra T A
SKSairam Krishnamurthy
Sairam Krishnamurthy
Sachchida Nand RaiSachchida Nand Rai
Sachchida Nand Rai
Background: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by beta-amyloid (Aβ) deposition and increased acetylcholinesterase (AchE) enzyme activities. Indole 3 carbinol (I3C) and diindolylmethane (DIM) are reported to have neuroprotective activities against various neurological diseases, including ischemic stroke, Parkinson’s disease, neonatal asphyxia, depression, stress, neuroinflammation, and excitotoxicity, except for AD. In the present study, we have investigated the anti-AD effects of I3C and DIM. Methods: Docking and molecular dynamic studies against AchE enzyme and network pharmacological studies were conducted for I3C and DIM. I3C and DIM’s neuroprotective effects against self and AchE-induced Aβ aggregation were investigated. The neuroprotective effects of I3C and DIM against Aβ-induced neurotoxicity were assessed in SH-S5Y5 cells by observing cell viability and ROS. Results: Docking studies against AchE enzyme with I3C and DIM show binding efficiency of −7.0 and −10.3, respectively, and molecular dynamics studies revealed a better interaction and stability between I3C and AchE and DIM and AchE. Network pharmacological studies indicated that I3C and DIM interacted with several proteins involved in the pathophysiology of AD. Further, I3C and DIM significantly inhibited the AchE (IC50: I3C (18.98 µM) and DIM (11.84 µM)) and self-induced Aβ aggregation. Both compounds enhanced the viability of SH-S5Y5 cells that are exposed to Aβ and reduced ROS. Further, I3C and DIM show equipotential neuroprotection when compared to donepezil. Conclusions: Our findings indicate that both I3C and DIM show anti-AD effects by inhibiting the Aβ induced neurotoxicity and AchE activities.

18 June 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRanajit Nivrutti Shinde
Ranajit Nivrutti Shinde
GKG Siva Kumar
G Siva Kumar
SEShahbaz Eqbal
Shahbaz Eqbal
MSMasilamani Elizabeth Sobhia
Masilamani Elizabeth Sobhia
Protein tyrosine phosphatase 1B (PTP1B) is a validated therapeutic target for Type 2 diabetes due to its specific role as a negative regulator of insulin signaling pathways. Discovery of active site directed PTP1B inhibitors is very challenging due to highly conserved nature of the active site and multiple charge requirements of the ligands, which makes them non-selective and non-permeable. Identification of the PTP1B allosteric site has opened up new avenues for discovering potent and selective ligands for therapeutic intervention. Interactions made by potent allosteric inhibitor in the presence of PTP1B were studied using Molecular Dynamics (MD). Computationally optimized models were used to build separate pharmacophore models of PTP1B and TCPTP, respectively. Based on the nature of interactions the target residues offered, a receptor based pharmacophore was developed. The pharmacophore considering conformational flexibility of the residues was used for the development of pharmacophore hypothesis to identify potentially active inhibitors by screening large compound databases. Two pharmacophore were successively used in the virtual screening protocol to identify potential selective and permeable inhibitors of PTP1B. Allosteric inhibition mechanism of these molecules was established using molecular docking and MD methods. The geometrical criteria values confirmed their ability to stabilize PTP1B in an open conformation. 23 molecules that were identified as potential inhibitors were screened for PTP1B inhibitory activity. After screening, 10 molecules which have good permeability values were identified as potential inhibitors of PTP1B. This study confirms that selective and permeable inhibitors can be identified by targeting allosteric site of PTP1B.

12 August 2011 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
HKHirdesh Kumar
Hirdesh Kumar
ASAnup Shah
Anup Shah
MSMasilamani Elizabeth Sobhia
Masilamani Elizabeth Sobhia

9 February 2012 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
MSMasilamani Elizabeth Sobhia
Masilamani Elizabeth Sobhia
SPStanly Paul
Stanly Paul
RSRanajit Shinde
Ranajit Shinde
MPMrudula Potluri
Mrudula Potluri
VGVenkatesh Gundam
Venkatesh Gundam
THThongtinlal Haokip
Thongtinlal Haokip
Introduction: The protein tyrosine phosphatases (PTPases or PTPs) are highly conserved phosphatases that regulate the tyrosine phosphorylation and consequently, the cellular functions. Protein tyrosine phosphorylation is the major post-translational modification to regulate signal transduction in cells. PTPs control diverse processes such as focal adhesion dynamics, cell–cell adhesion, insulin signaling, cytoskeletal functions, synaptogenesis and neurite growth. The availability of numerous X-ray crystal structures of PTPs, along with their inhibitors, has provided the opportunity for the structure-based design of effective inhibitors having potential for the treatment of various disorders. Areas covered: The main focus of the present review is to get an insight into the most clinically relevant therapeutic PTP inhibitors published in patents over the past 10 years. Expert opinion: Several computational studies are being carried out to understand ligand binding modes, selectivity interactions and conformational changes during inhibitor binding. PTP inhibitors that are of current interest include quinolyl, cyclic alabenzimidazole, pyrazine, (ethynediyl)bis-benzene, pyridopyrimidine, triazolopyridine, cyclo propylphenyl phenyloxamides, oxindole and azoloarin derivatives. The development of allosteric site-directed PTP inhibitors may help in understanding the absorption and selectivity of PTP inhibitors.

29 July 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
HKHarish Kumar
Harish Kumar
MSMasilamani Elizabeth Sobhia
Masilamani Elizabeth Sobhia

19 April 2015 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
PIPoornima Iyer
Poornima Iyer
JBJahnavi Bolla
Jahnavi Bolla
VKVivek Kumar
Vivek Kumar
MGManjinder Singh Gill
Manjinder Singh Gill
MSMasilamani Elizabeth Sobhia
Masilamani Elizabeth Sobhia